Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW BUDOFF

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1811967433
CMS profile
127894
Location
TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$558,227.34

432 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 9; records 151–200 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW BUDOFF

NPI 1811967433 · CMS profile ID 127894

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 9; records 151–200 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 9; records 151–200 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 9; records 151–200 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 9; records 151–200 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

432 matching records · $558,227.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 432 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 432.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $157.9207/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811308845 CMS
AstraZeneca Pharmaceuticals LP $1,050.0007/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829488109 CMS
Novo Nordisk Inc $101.4507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811156491 CMS
Novo Nordisk Inc $7,687.5007/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811599801 CMS
Novo Nordisk Inc $140.0007/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811696909 CMS
PFIZER INC. $8.3107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832710009 CMS
PFIZER INC. $19.9107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832753127 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $7.0907/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768809214 CMS
Regeneron Healthcare Solutions, Inc. $1,170.0007/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562633 CMS
AstraZeneca Pharmaceuticals LP $300.0007/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829298955 CMS
Novo Nordisk Inc $5,812.5007/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810652537 CMS
Novo Nordisk Inc $120.8607/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810780009 CMS
Novo Nordisk Inc $44.8007/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811453349 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.0007/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763786472 CMS
Janssen Pharmaceuticals, Inc $18.3707/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788711603 CMS
AstraZeneca Pharmaceuticals LP $4,300.0007/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829928687 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $16.2807/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768809212 CMS
AstraZeneca Pharmaceuticals LP $1,050.0007/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829388723 CMS
Esperion Therapeutics, Inc. $2,900.0007/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255513 CMS
Janssen Pharmaceuticals, Inc $18.2007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788711601 CMS
Esperion Therapeutics, Inc. $44.8006/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255505 CMS
Esperion Therapeutics, Inc. $124.8806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255507 CMS
Esperion Therapeutics, Inc. $4,640.0006/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255511 CMS
AstraZeneca Pharmaceuticals LP $2,150.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829947701 CMS
Kowa Pharmaceuticals America, Inc. $125.0006/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805435693 CMS
Lilly USA, LLC $750.0006/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818610501 CMS
Lilly USA, LLC $1,450.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818649459 CMS
AstraZeneca Pharmaceuticals LP $1,050.0006/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829612257 CMS
AstraZeneca Pharmaceuticals LP $1,050.0006/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829717383 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763412938 CMS
Lilly USA, LLC $1,200.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818602385 CMS
AstraZeneca Pharmaceuticals LP $104.8006/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829702483 CMS
AstraZeneca Pharmaceuticals LP $26.7306/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829735229 CMS
AstraZeneca Pharmaceuticals LP $258.7706/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829788147 CMS
AstraZeneca Pharmaceuticals LP $96.2806/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829931793 CMS
AstraZeneca Pharmaceuticals LP $221.8006/23/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829993731 CMS
Esperion Therapeutics, Inc. $2,900.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255489 CMS
Esperion Therapeutics, Inc. $3,400.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255493 CMS
Esperion Therapeutics, Inc. $3,400.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255495 CMS
Esperion Therapeutics, Inc. $4,900.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255499 CMS
Esperion Therapeutics, Inc. $3,360.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255501 CMS
Esperion Therapeutics, Inc. $59.3306/18/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255471 CMS
Esperion Therapeutics, Inc. $13.6206/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255473 CMS
Esperion Therapeutics, Inc. $35.6106/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255477 CMS
Esperion Therapeutics, Inc. $54.9906/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255481 CMS
Esperion Therapeutics, Inc. $37.7506/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255483 CMS
Esperion Therapeutics, Inc. $32.5406/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255487 CMS
AstraZeneca Pharmaceuticals LP $1,050.0006/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830028901 CMS
Esperion Therapeutics, Inc. $14.7306/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255463 CMS
Esperion Therapeutics, Inc. $76.7306/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838255467 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $640,390.46 660
PY2020 $407,996.72 367
PY2021 $558,227.34 432
PY2022 $487,475.55 435
PY2023 $407,315.94 383
PY2024 $574,074.03 406
PY2025 $541,709.23 454

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $19,093.06 9
PY2025 Principal investigator $1,159,945.76 40
PY2024 Recipient $474,548.50 3
PY2024 Principal investigator $876,843.21 71
PY2023 Recipient $65,346.50 3
PY2023 Principal investigator $910,851.85 113
PY2022 Recipient $1,794.49 8
PY2022 Principal investigator $783,031.83 111
PY2021 Recipient $940.00 1
PY2021 Principal investigator $1,077,613.94 313
PY2020 Recipient $21,712.08 10
PY2020 Principal investigator $1,440,514.07 410
PY2019 Principal investigator $1,441,179.18 581

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,108.34 12/31/2025 Non-covered Recipient Entity
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920281
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $200.00 12/23/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV No dispute reported 06/30/2026 1225415010
Recipient Cleerly, Inc. $750.00 12/05/2025 Covered Recipient Physician TRANSFORM No dispute reported 06/30/2026 1241147830
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,100.00 12/03/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185552741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,900.00 11/30/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185552743
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 11/30/2025 Non-covered Recipient Entity
LAYOUS MEDICAL GROUP
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185552747
Principal investigator 1 Cleerly, Inc. $1,345.00 11/26/2025 Non-covered Recipient Entity
The Lunquist Institute
Confirm2 No dispute reported 06/30/2026 1241147496
Principal investigator 1 Novo Nordisk AS $1,333.32 10/31/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
NN9535-4321 No dispute reported 06/30/2026 1213747164
Recipient Novartis Pharma AG $284.36 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109417
Recipient Novartis Pharma AG $484.08 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109419
Recipient Novartis Pharma AG $188.35 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109421
Recipient Novartis Pharma AG $184.27 10/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109423
Principal investigator 1 Novartis Pharmaceuticals Corporation $203.67 10/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302351
Principal investigator 1 Ionis Pharmaceuticals, Inc. $100.00 10/21/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246789500
Principal investigator 1 Ionis Pharmaceuticals, Inc. $9,100.00 10/16/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246789371
Principal investigator 1 GE HEALTHCARE $91,518.11 10/15/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
20HC-G-Cardiac CT Deblooming No dispute reported 06/30/2026 1244366631
Principal investigator 1 GE HEALTHCARE $83,182.54 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
20HC-G-Cardiac CT Deblooming No dispute reported 06/30/2026 1244366627
Principal investigator 1 GE HEALTHCARE $140,180.56 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
20HC-G-Cardiac CT Deblooming No dispute reported 06/30/2026 1244366629
Principal investigator 1 Ionis Pharmaceuticals, Inc. $650.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788352
Principal investigator 1 Ionis Pharmaceuticals, Inc. $675.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788356
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,000.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788359
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,275.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788363
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,380.00 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788368
Principal investigator 1 Ionis Pharmaceuticals, Inc. $13,770.39 10/08/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246788371
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,836.61 09/02/2025 Non-covered Recipient Entity
HARBOR - UCLA MEDICAL CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190301467
Recipient Novartis Pharma AG $92.55 08/29/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109839
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,300.00 08/22/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185552737
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,469.02 08/06/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246786044
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 07/10/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246785187
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,500.00 07/10/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
IS354CS9 No dispute reported 06/30/2026 1246785191
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $9,375.30 06/30/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV No dispute reported 06/30/2026 1225412308
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,520.00 05/08/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV No dispute reported 06/30/2026 1225412712
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $344.00 04/30/2025 Non-covered Recipient Entity
Lundquist Inst For Biomed At Harbor-ucla Medical
BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti No dispute reported 06/30/2026 1225403743
Principal investigator 1 Amgen Inc. $36,550.00 04/24/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246643704
Recipient Amgen Inc. $2,909.45 03/31/2025 Covered Recipient Physician P4 Global Vesalius Real No dispute reported 06/30/2026 1246637206
Principal investigator 1 Novo Nordisk AS $9,812.39 03/31/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
EX9924-4473 No dispute reported 06/30/2026 1213814680
Principal investigator 1 Cleerly, Inc. $119.49 03/24/2025 Non-covered Recipient Entity
The Lunquist Institute
Confirm2 No dispute reported 06/30/2026 1241147438
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,152.60 03/24/2025 Non-covered Recipient Entity
HARBOR - UCLA MEDICAL CENTER
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190308160
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,570.99 03/12/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE BIOMED AT HARBOR
A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag No dispute reported 06/30/2026 1190305617
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,434.78 02/27/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190301891
Principal investigator 1 Novo Nordisk AS $1,700.00 02/21/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
EX9924-4473 No dispute reported 06/30/2026 1213744553
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,578.50 02/05/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA
REALIZE-K Phase IV, randomized, double-blind, placebo-controlled, parallel-group trial evaluating Sodium Zirconium Cyclosilicate (SZC) for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction, chronic kidney disease and receiving spironolactone No dispute reported 06/30/2026 1185552739
Principal investigator 1 Amgen Inc. $28,026.40 01/30/2025 Non-covered Recipient Entity
HARBOR UNIVERSITY OF CALIFORNIA LOS ANGELES MEDICAL CENTER
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246642048
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,748.20 01/30/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190301889
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,032.00 01/30/2025 Non-covered Recipient Entity
THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION
A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag No dispute reported 06/30/2026 1190301893
Recipient Novartis Pharma AG $4,200.00 01/28/2025 Covered Recipient Physician CKJX839D12303 No dispute reported 06/30/2026 1248109841
Principal investigator 1 Novartis Pharmaceuticals Corporation $101,683.95 01/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302551
Principal investigator 1 Novartis Pharmaceuticals Corporation $409,869.60 01/06/2025 Non-covered Recipient Entity
LUNDQUIST INSTITUTE BIOMED AT HARBOR
Imaging Long/term study of Inclisiran on Atherosclerotic Disease (ILIAD) Trial No dispute reported 06/30/2026 1190305615
Recipient Canon Medical Informatics, Inc. $10,000.00 01/01/2025 Covered Recipient Physician Cardiac Analysis No dispute reported 06/30/2026 1254963070